Full-Time

Manufacturing Engineering AI Enablement Lead

Updated on 9/15/2026

Illumina

Illumina

5,001-10,000 employees

Develops sequencing platforms and consumables

Compensation Overview

$141.6k - $212.4k/yr

+ Bonus or commission + Equity

No H1B Sponsorship

San Diego, CA, USA

In Person

Bachelor's, Master's, PhD

Category
Business & Strategy (1)
Required Skills
LLM
Agile
ERP
Six Sigma
UiPath

Get referred to Illumina

See people who can refer or advise you

Requirements
  • Typically requires 12+ years of related experience with a Bachelor's degree, or 10+ years with a Master's degree, or a PhD with 8+ years of experience, or equivalent practical experience.
  • At least 10 years of experience in Global Operations, Manufacturing, Quality, or related environments.
  • Ability to influence senior stakeholders and drive cross-functional transformation.
  • Strong understanding of life sciences manufacturing processes and systems, including LIMS, EAM, Industry 4.0, Digital Twin, and OT environments.
  • Understanding of applied AI, agentic AI, and automation capabilities, including LLMs, workflow automation, and predictive models.
  • Technical fluency to lead and partner across AI engineering, automation development, and low-code platforms.
  • Experience with RPA, LLMs, orchestration tools, or process mining, including tools such as UiPath, Azure OpenAI, Microsoft Copilot Studio, and Anthropic.
  • Experience managing global project portfolios, agile teams, and end-to-end solution delivery lifecycles.
Responsibilities
  • Partner with manufacturing sites and value streams to identify high-value AI and automation opportunities and shape an actionable demand pipeline.
  • Facilitate discovery sessions, process reviews, and value assessments to align opportunities with operational priorities.
  • Translate operational challenges into well-defined AI and automation use cases, solution concepts, and ROI projections.
  • Partner with IT and business stakeholders to execute RPA, Generative AI, and Agentic AI solutions.
  • Lead intake, scoping, sprint planning, and delivery to ensure solutions are scalable, maintainable, and aligned with enterprise AI governance and AI Center of Excellence practices.
  • Collaborate with IT Automation and AI teams and platform owners to ensure technology readiness, security, and compliance.
  • Assess and drive adoption of AI capabilities integrated with SAP EAM, Industry 4.0, Digital Twin, and other OT and manufacturing technologies.
  • Design and deploy training programs to accelerate AI literacy and adoption across manufacturing operations.
  • Develop enablement assets including playbooks, FAQs, demos, usage guidelines, and citizen-developer guardrails.
  • Establish feedback loops to continuously improve training, tooling, and solution usability across functions.
  • Upskill manufacturing teams to leverage AI in their day-to-day work.
  • Drive change-management strategies that support new AI solutions and ensure stakeholder engagement, communication, and user readiness.
  • Track adoption and performance metrics, measure business impact, and report value realization to senior leadership.
  • Support cultural transformation toward data-driven, AI-enabled manufacturing operations.
  • Contribute to Global Operations' AI roadmap, aligning AI capabilities with long-term operational excellence and innovation goals.
  • Stay current on AI, LLM, and automation trends and apply insights to guide technology evolution and solution design.
  • Champion responsible, secure, and value-driven AI adoption across the enterprise.
Desired Qualifications
  • Hands-on experience deploying AI and automation solutions in complex operational environments.
  • Familiarity with enterprise AI governance, risk management, and compliance frameworks.
  • Exposure to MES, QMS, ERP, planning systems, or related manufacturing technologies.
  • Lean, Six Sigma, or operational excellence certification.

Illumina provides integrated sequencing platforms and related consumables for analyzing genetic variation and biological function. Its instruments range from high-throughput NovaSeq systems to benchtop MiSeq/iSeq units, all built on sequencing-by-synthesis technology acquired from Solexa. Revenue comes from instrument sales plus a recurring stream of consumables, reagents, library preparation kits, and services. The company differentiates itself with a broad end-to-end ecosystem and strategic acquisitions (Solexa, GRAIL, SomaLogic) that expand capabilities into multiomics and clinical diagnostics.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

1998

Get referred to Illumina

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Illumina raised 2026 revenue guidance to $4.60 billion-$4.64 billion after Q2 strength.
  • S&P 500 inclusion on September 21, 2026 should drive passive-fund buying.
  • Clinical volume reached 78% NovaSeq X conversion, supporting recurring consumables growth.

What critics are saying

  • FTC and Fifth Circuit GRAIL litigation still threatens forced divestiture and management distraction.
  • Research consumables declined in 2026 while clinical demand carried growth, exposing narrow dependence.
  • BGI and Thermo Fisher keep pressuring sequencing pricing, risking margin compression by 2027.

What makes Illumina unique

  • NovaSeq X drives clinical sequencing workflows, with 95 placements in Q2 2026.
  • Illumina pairs sequencing, DRAGEN software, and multiomics tools into one platform.
  • The new WGS MRD research solution broadens Illumina beyond core sequencing instruments.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

-2%
Yahoo Finance
Sep 9th, 2026
Illumina joins S&P 500 on 21 September following 112% stock surge

Illumina will join the S&P 500 index on 21 September, alongside Bloom Energy and Everpure, replacing Molson Coors Beverage, The Trade Desk, and Builders FirstSource. S&P Dow Jones Indices announced the rebalancing on Friday. The San Diego-based genetic sequencing company, valued at $33 billion, has returned 112% over the past 12 months. The inclusion will trigger buying from passive funds tracking the index. Illumina is moving from the S&P MidCap 400, signalling its growth into large-cap status. In the second quarter, the company reported revenue of $1.16 billion, up 9.5% year-over-year, with earnings per share rising approximately 10% to $1.31.

Yahoo Finance
Aug 26th, 2026
Illumina beats Q2 expectations with $1.16B revenue, raises full-year guidance

Illumina reported second-quarter revenues of $1.16 billion, marking a 9.4% year-on-year increase that exceeded analyst expectations by 2.5%. The DNA sequencing and microarray technology company delivered strong organic revenue performance and raised its full-year earnings guidance. Chief executive Jacob Thaysen attributed the results to growing momentum in sequencing-intensive applications among clinical customers. The company increased its revenue and earnings guidance for the year based on this performance. Illumina's shares rose 10% following the earnings announcement and currently trade at $225.55. The results came as part of a strong second quarter for the life sciences tools and services sector overall, with the 20 tracked stocks in the group beating revenue estimates by 2.6% on average.

GenomeWeb
Aug 14th, 2026
Illumina secures $1B credit facility with Bank of America, launches note offering

Illumina has entered into a $1 billion credit facility with Bank of America serving as administrative agent. The genomics company announced the agreement after market close on Thursday. The credit facility also includes an underwriting agreement for a note offering, though specific terms were not disclosed in the announcement.

AktienSensor
Aug 12th, 2026
Illumina raises $750M with 2029 senior notes to refinance debt and lower cost of capital

Illumina has filed to issue senior notes maturing in 2029, expecting to raise approximately $750 million. The unsecured notes will rank equally with the company's other unsecured debt and feature a yield near the current US Treasury benchmark. Proceeds will primarily repay an earlier 4.65% note due in September 2026. By extinguishing higher-cost debt, Illumina aims to reduce its interest burden and improve its debt-to-equity ratio. The company expects its weighted average cost of capital to decrease from 5.8% to an estimated 4.9%. The notes include a make-whole redemption clause and a change-of-control provision requiring Illumina to purchase notes at 101% of principal plus interest. Illumina holds Moody's A-3 and S&P A- credit ratings. The refinancing supports ongoing investment in next-generation sequencing platforms, data analytics, and cloud-based services whilst enhancing financial flexibility for strategic acquisitions and R&D funding.

PR Newswire
Jul 30th, 2026
Illumina raises 2026 guidance on strong Q2 results: $1.16B revenue, up 9.5%

Illumina reported second quarter 2026 revenue of $1.16 billion, up 9.5% from the prior year period. The San Diego-based genomics company posted GAAP diluted earnings per share of $1.35 and non-GAAP diluted earnings per share of $1.31. Chief executive Jacob Thaysen said momentum built through the first half of 2026 as the company's technology enabled clinical customers to expand sequencing-intensive applications. He noted that demand for NovaSeq X remains high. Based on this performance, Illumina raised its full-year 2026 revenue guidance to $4.60-$4.64 billion, up from prior guidance of $4.52-$4.62 billion. The company increased its non-GAAP diluted earnings per share guidance to $5.30-$5.40, versus prior guidance of $5.15-$5.30.